All episodes

24 min

Mechanisms Behind the Disease: Understanding the Role of APRIL in IgAN Pathogenesis: A Podcast

This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the journal's website and by using this link: https://link.springer.com/article/10.1007/s12325-026-03840-9. All conflicts of interest can be found online. This podcast is intended for medical professionals.

Open Access. This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate...

36 min

Understanding the Patient Journey in Extrapulmonary Neuroendocrine Carcinoma: A Podcast

In this podcast, Aman Chauhan from the Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA, USA, Deborah Robertson, patient advocate, Lombard, IL, USA, and Susan Meckler-Plummer from Minkahz NETs Mission, Atlanta, GA, USA discuss the diagnosis and treatment of extrapulmonary neuroendocrine carcinoma, highlighting challenges and unmet needs from the perspectives of a medical oncologist, patient, caregiver, and patient advocacy group founder.
This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted Oncology website and by using this link: https://link.springer.com/article/10.1007/s11523-026-01262-9. All conflicts...

36 min

Dengue Vodcast: Insights from Recent Infectious Disease Congresses

Dengue Vodcast: Insights from Recent Infectious Disease Congresses

This podcast is published open access in Infectious Diseases and Therapy, and is fully citeable. You can access the original published podcast article through the Infectious Diseases and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40121-026-01428-y. All conflicts of interest can be found online. This podcast is intended for medical professionals.

Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and...

33 min

A Podcast on Osimertinib After CRT in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)

In this podcast, Thanyanan Reungwetwattana from the Division of Medical Oncology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, Kristin A. Higgins from the Department of Radiation Oncology, City of Hope Cancer Center Atlanta, Atlanta, GA, USA, Ignacio Casarini from the Servicio Oncología, Hospital Bernardo Houssay, Mar del Plata, Buenos Aires, Argentina, and Suresh S. Ramalingam from the Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USA discuss considerations surrounding the implementation of the LAURA (NCT03521154) regimen (osimertinib after chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer) in clinical...

34 min

Perspectives on 10 years of Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: A Podcast

In this podcast, Shailender Bhatia from the Division of Hematology and Oncology, Department of Medicine, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA, Sandra D’Angelo from the Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA, and Paul Nghiem from the Department of Dermatology, University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, USA summarize key studies of ICIs in advanced MCC, including clinical trials and real-world studies, and discuss clinical evidence related to practical considerations, such as elective discontinuation of ICI treatment, and treatment...

44 min

Management of Adverse Events Associated with MET TKIs in Patients with Advanced NSCLC: A Podcast Discussion

In this podcast, Wade T. Iams from the Greco-Hainsworth Centers for Research Tennessee Oncology, Nashville, TN, USA and Narjust Florez form the Dana-Farber Cancer Institute and the Harvard Medical School, Boston, MA, USA discuss safety considerations with MET TKI treatment for patients with METex14 skipping NSCLC.
This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted Oncology website and by using this link: https://link.springer.com/article/10.1007/s11523-026-01242-z. All conflicts of interest can be found online.
Open Access: This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License,...

36 min

Risk of Recurrence in Patients with HR+/HER2− Early Breast Cancer: A Podcast

In this podcast, Maryam B. Lustberg from the Smilow Cancer Hospital at Yale, New Haven, CT, USA, Megan-Claire Chase, Life on the Cancer Train, Atlanta, GA, USA, Stacey Tinianov, Advocates for Collaborative Education, Santa Cruz, CA, USA, and Kevin Kalinsky from the Winship Cancer Institute at Emory University, Atlanta, GA, USA discuss the risk of recurrence for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer including early and late risk of recurrence, discuss how risk is assessed, and examine the evolving treatment landscape for reducing risk..
This podcast is published open access in Targeted Oncology and...

45 min

Expert Perspectives on TGCT & the Outcomes of the Phase 3 MANEUVER Study of Pimicotinib Presented at ASCO and ESMO 2025

Expert Perspectives on TGCT and the Outcomes of the Phase 3 MANEUVER Study of Pimicotinib Presented at ASCO and ESMO 2025: A Podcast Discussion

In this podcast article, the authors share their perspectives on current treatment for the rare, locally aggressive neoplasm, tenosynovial giant cell tumor (TGCT). They also discuss the patient care journey in the US, and highlight the clinical significance of the MANEUVER study findings.

This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link:...

26 min

Four-Year Outcomes of Faricimab in Diabetic Macular Edema in the RHONE-X Extension Trial: A Podcast

This podcast is published open access in Ophthalmology and Therapy and is fully citeable. You can access the original published podcast article through the Ophthalmology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40123-026-01470-6. All conflicts of interest can be found online. This podcast is intended for medical professionals.

Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence,...

18 min

Vodcast on Real-World Comparative OS and PFS of CDK4/6 Inhibitors Plus an AI in the P-VERIFY Study

In this podcast, Hope S. Rugo from the Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA provides an overview of two recent publications reporting overall survival (OS) and real-world progression-free survival (rwPFS) results from P-VERIFY, a retrospective comparative effectiveness study of CDK4/6 inhibitors plus an aromatase inhibitor (AI) among patients with HR+/HER2− mBC treated in routine clinical practice in the USA.
This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted Oncology website and by using this link:...